MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

<P>MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling.</P> <P>In general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases.</P>

MEK Inhibitors, Antagonists & Activators

Anemarsaponin B

Cat. No.: HY-N0811

Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of **iNOS** and **COX-2**. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

APS-2-79

Cat. No.: HY-100627

APS-2-79 is a **KSR**-dependent **MEK** antagonist. APS-2-79 inhibits ATP^{biotin} binding to KSR2 within the KSR2-MEK1 complexe with an IC_{50} of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APS-2-79 hydrochloride

Cat. No.: HY-100627A

APS-2-79 hydrochloride is a **KSR**-dependent **MEK** antagonist. APS-2-79 inhibits ATP^{biotin} binding to KSR2 within the KSR2-MEK1 complexe with an IC_{50} of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD8330

(ARRY-424704; ARRY-704)

Cat. No.: HY-12058

AZD8330 (ARRY-424704) is a potent, uncompetitive **MEK1/MEK2** inhibitor, with an IC_{50} of 7 nM.



Purity: 99.14%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Balamapimod

(MKI 833)

Cat. No.: HY-14947

Balamapimod (MKI 833) is a reversible **Ras/Raf/MEK** inhibitor with potential anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-847325

Cat. No.: HY-18955

BI-847325 is an ATP competitive dual inhibitor of **MEK** and aurora kinases (**AK**) with IC_{50} values of 4 and 15 nM for human MEK2 and AK-C, respectively.



Purity: 98.66%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Binimetinib

(MEK162; ARRY-162; ARRY-438162)

Cat. No.: HY-15202

Binimetinib (MEK162) is an oral and selective **MEK1/2** inhibitor. Binimetinib (MEK162) inhibits **MEK** with an IC_{50} of 12 nM.



Purity: 99.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Binimetinib-13C,d3

(MEK162-13C,d3; ARRY-162-13C,d3; ARRY-438162-13C,d3)

Cat. No.: HY-15202S

Binimetinib-13C,d3 (MEK162-13C,d3) is the 13C- and deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective **MEK1/2** inhibitor. Binimetinib (MEK162) inhibits **MEK** with an IC_{50} of 12 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIX02188

Cat. No.: HY-12055

BIX02188 is a potent **MEK5**-selective inhibitor with an IC_{50} of 4.3 nM. BIX02188 inhibits **ERK5** catalytic activity, with an IC_{50} of 810 nM.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BIX02189

Cat. No.: HY-12056

BIX02189 is a potent and selective **MEK5** inhibitor with an IC_{50} of 1.5 nM. BIX02189 also inhibits **ERK5** catalytic activity with an IC_{50} of 59 nM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

C16-PAF

(PAF (C16))

Cat. No.: HY-108635

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (**PAFR**). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CI-1040

(PD 184352)

Cat. No.: HY-50295

CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of **MEK** with an IC_{50} of 17 nM for MEK1.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Cobimetinib

(GDC-0973; XL518)

Cat. No.: HY-13064

Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral **MEK1** inhibitor with an IC_{50} of 4.2 nM for **MEK1**.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cobimetinib (R-enantiomer)

(GDC-0973 R-enantiomer; XL-518 R-enantiomer)

Cat. No.: HY-13079

Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Cobimetinib hemifumarate

(GDC-0973 hemifumarate; XL-518 hemifumarate)

Cat. No.: HY-13064A

Cobimetinib hemifumarate is a novel selective **MEK1** inhibitor, and the IC_{50} value against MEK1 is 4.2 nM.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cobimetinib racemate

(GDC-0973 racemate; XL518 racemate)

Cat. No.: HY-13078

Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cobimetinib-d4

(GDC-0973-d4; XL518-d4)

Cat. No.: HY-13064S

Cobimetinib-d4 (GDC-0973-d4) is the deuterium labeled Cobimetinib. Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral **MEK1** inhibitor with an IC_{50} of 4.2 nM for **MEK1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E6201

(ER-806201)

Cat. No.: HY-15496

E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of **MEK1** and **FLT3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EBI-1051

Cat. No.: HY-111368

EBI-1051 is a highly potent and orally efficacious **MEK** inhibitor with an IC_{50} of 3.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GDC-0623

(RG 7421; MEK inhibitor 1)

Cat. No.: HY-15610

GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of **MEK1** (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC_{50}=42 nM) versus A375 ($BRAF^{V600E}$, EC_{50}=7 nM).



Purity: 99.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gossypetin

Cat. No.: HY-119917

Gossypetin is a hexahydroxylated flavonoid and is a potent **mitogen-activated protein kinase kinase (MKK)3** and **MKK6** inhibitor with strongly attenuates the **MKK3/6-p38** signaling pathway, has various pharmacological activities, including antioxidant, antibacterial...



Purity: 99.82%
Clinical Data: No Development Reported
Size: 1 mg

GW284543

(UNC10225170)

Cat. No.: HY-114189

GW284543 (UNC10225170) is a selective **MEK5** inhibitor. GW284543 (UNC10225170) reduces pERK5, and decreases endogenous MYC protein.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

Isorhamnetin

(3'-Methylquercetin)

Cat. No.: HY-N0776

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isorhamnetin-d3

(3'-Methylquercetin-d3)

Cat. No.: HY-N0776S

Isorhamnetin-d3 (3'-Methylquercetin-d3) is the deuterium labeled Isorhamnetin. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lidocaine

(Lignocaine)

Cat. No.: HY-B0185

Lidocaine (Lignocaine) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Lidocaine hydrochloride

(Lignocaine hydrochloride)

Cat. No.: HY-B0185A

Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Lidocaine-d10

Cat. No.: HY-B0185S1

Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lidocaine-d10 hydrochloride

Cat. No.: HY-B0185AS

Lidocaine-d10 (Lignocaine-d10) hydrochloride is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

Lidocaine-d10 N-Oxide

Cat. No.: HY-B0185S

Lidocaine-d10 N-Oxide is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Lidocaine-d6 hydrochloride

(Lignocaine-d6 hydrochloride)

Cat. No.: HY-B0185AS1

Lidocaine-d6 (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAP855

Cat. No.: HY-145702

MAP855 is a highly potent, selective, ATP-competitive and orally active **MEK1/2** kinase inhibitor (MEK1 ERK2 cascade IC_{50}=3 nM, pERK EC_{50}=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MEK inhibitor

Cat. No.: HY-12202

MEK inhibitor is a potent **MEK** inhibitor with antitumor potency.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MEK-IN-1

Cat. No.: HY-U00312

MEK-IN-1 is a **MEK** inhibitor extracted from patent WO2008076415A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MEK-IN-5

Cat. No.: HY-143468

MEK-IN-5 is a potent **MEK** inhibitor and NO donor. MEK-IN-5 significantly reduces the levels of pMEK and pERK in a dose-dependent and time-dependent manner. MEK-IN-5 induces **apoptosis** in MDA-MB-231 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MEK1/2-IN-2

Cat. No.: HY-145701

MEK1/2-IN-2 is a potent ATP-competitive **MEK1/2** inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MEK4 inhibitor-1

Cat. No.: HY-139638

MEK4 inhibitor-1 is a novel **MEK4** inhibitor against pancreatic adenocarcinoma with an IC_{50} value of 61 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MEK4 inhibitor-2

Cat. No.: HY-139639

MEK4 inhibitor-2 is a novel **MEK4** inhibitor against pancreatic adenocarcinoma with an IC_{50} value of 83 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mirdametinib

(PD0325901; PD325901)

Cat. No.: HY-10254

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive **MEK** inhibitor with an IC_{50} of 0.33 nM. Mirdametinib exhibits a K_i^{app} of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces **apoptosis**.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS432

Cat. No.: HY-130602

MS432 is a first-in-class and highly selective PD0325901-based **von Hippel-Lindau**-recruiting **PROTAC** degrader for **MEK1** and **MEK2**. MS432 displays good plasma exposure in mice, exhibiting DC_{50} values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD 198306

Cat. No.: HY-107620

PD 198306 is a selective MAPK/ERK-kinase (**MEK**) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-334581

Cat. No.: HY-107619

PD-334581 is a **MEK1** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD0325901-O-C2-dioxolane

Cat. No.: HY-131295

PD0325901-O-C2-dioxolane has main portion of **MEK** inhibitor PD0325901.
PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD184161

Cat. No.: HY-10174

PD184161 is an orally active **MEK** inhibitor.
PD184161 inhibits MEK activity (IC_{50}=10-100 nM) in a time- and concentration-dependent manner.
PD184161 inhibits cell proliferation and induces **apoptosis**. PD184161 produces depressive-like behavior.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD318088

Cat. No.: HY-12062

PD318088 is a potent, allosteric and non-ATP competitive **MEK1/2** inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD98059

Cat. No.: HY-12028

PD98059 is a potent and selective **MEK** inhibitor with an IC_{50} of 5 μM. PD98059 binds to the inactive form of **MEK**, thereby preventing the activation of **MEK1** (IC_{50} of 2-7 μM) and **MEK2** (IC_{50} of 50 μM) by upstream kinases. PD98059 is a **ERK1/2** signaling inhibitor.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pimasertib

(AS703026; MSC1936369B)

Cat. No.: HY-12042

Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available **MEK1/2** inhibitor.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Refametinib

(BAY 869766; RDEA119)

Cat. No.: HY-14691

Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric **MEK1/MEK2** inhibitor with IC_{50}s of 19 nM and 47 nM, respectively.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Refametinib (R enantiomer)

(BAY 869766 R enantiomer; RDEA119 R enantiomer)

Cat. No.: HY-10216

Refametinib R enantiomer is a **MEK** inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC_{50} of 2.0-15 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.07%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ro 5126766

(CH5126766)

Cat. No.: HY-18652

Ro 5126766 (CH5126766) is a first-in-class dual **MEK/RAF** inhibitor that allosterically inhibits **$BRAF^{V600E}$**, **CRAF**, **MEK**, and **BRAF** (IC_{50}: 8.2, 56, 160 nM, and 190 nM, respectively).



Purity: 98.19%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RO4987655

(CH4987655)

Cat. No.: HY-14719

RO4987655 is an orally active and highly selective **MEK** inhibitor with an IC_{50} of 5.2 nM for inhibition of **MEK1/MEK2**.



Purity: 99.26%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Selumetinib

(AZD6244; ARRY-142886)

Cat. No.: HY-50706

Selumetinib (AZD6244) is selective, non-ATP-competitive oral **MEK1/2** inhibitor, with an IC_{50} of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Selumetinib sulfate

(AZD6244 sulfate; ARRY-142886 sulfate)

Cat. No.: HY-50706A

Selumetinib (AZD6244) is selective, non-ATP-competitive oral **MEK1/2** inhibitor, with an IC_{50} of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Selumetinib-d4

(AZD6244-d4; ARRY-142886-d4)

Cat. No.: HY-50706S

Selumetinib-d4 (AZD6244-d4) is the deuterium labeled Selumetinib. Selumetinib (AZD6244) is selective, non-ATP-competitive oral **MEK1/2** inhibitor, with an IC_{50} of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SL327

Cat. No.: HY-15437

SL327 inhibits **MEK1** and **MEK2**, with IC_{50} values of 180 nM and 220 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TAK-733

Cat. No.: HY-13449

TAK-733 is a potent and selective **MEK** allosteric site inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.48%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Trametinib

(GSK1120212; JTP-74057)

Cat. No.: HY-10999

Trametinib (GSK1120212; JTP-74057) is an orally active **MEK** inhibitor that inhibits MEK1 and MEK2 with IC_{50}s of about 2 nM. Trametinib activates **autophagy** and induces **apoptosis**.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trametinib (DMSO solvate)

(GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)) Cat. No.: HY-10999A

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active **MEK** inhibitor that inhibits MEK1 and MEK2 with IC_{50}s of about 2 nM. Trametinib (DMSO solvate) activates **autophagy** and induces **apoptosis**.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trametinib-13C,d3

(GSK1120212-13C,d3; JTP-74057-13C,d3) Cat. No.: HY-10999S2

Trametinib-13C,d3 is the 13C- and deuterium labeled. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trametinib-13C6

Cat. No.: HY-10999S1

Trametinib-13C6 is the 13C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active **MEK** inhibitor that inhibits MEK1 and MEK2 with IC_{50}s of about 2 nM. Trametinib activates **autophagy** and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trametinib-d4

Cat. No.: HY-10999S

Trametinib-d4 is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active **MEK** inhibitor that inhibits MEK1 and MEK2 with IC_{50}s of about 2 nM. Trametinib activates **autophagy** and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

trans-Zeatin

Cat. No.: HY-19700

trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced **MEK/ERK** activation.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

trans-Zeatin-d5

Cat. No.: HY-19700S

trans-Zeatin-d5 is deuterium labeled trans-Zeatin. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

U0124

Cat. No.: HY-107621

U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

U0126

Cat. No.: HY-12031A

U0126 is a potent, non-ATP competitive and selective **MEK1** and **MEK2** inhibitor, with IC_{50}s of 72 nM and 58 nM, respectively. U0126 is an **autophagy** and **mitophagy** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

U0126-EtOH

Cat. No.: HY-12031

U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective **MEK1** and **MEK2** inhibitor, with IC_{50}s of 72 nM and 58 nM, respectively. U0126 is an **autophagy** and **mitophagy** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Xantocillin

(Xanthocillin X) Cat. No.: HY-122404

Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces **autophagy** through inhibition of the **MEK/ERK** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Zapnometinib

(PD0184264; ATR-002) Cat. No.: HY-139558

Zapnometinib (PD0184264), an active metabolite of CI-1040, is a **MEK** inhibitor, with an IC_{50} of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg